Clinical trial NCT05521542: Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease
Official title: ADVANCEd NanoTherapies Dual Active Pharmacological Ingredient (Dual-API) Drug-Coated Balloon Catheter to Treat De-Novo Lesions in Patients With Symptomatic Stable Angina, Unstable Angina, and NSTEMI
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Coronary Artery Disease
Keywords: Drug Coated Ballon
DCB
Coronary Artery Disease
Lead sponsor: Advanced NanoTherapies
Sponsor class: INDUSTRY
Collaborators: name: Monash University
name: Cardiovascular Research Foundation, New York
First posted: 2022-08-30
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Prospective, multi-center, single-arm, feasibility study
Primary purpose: TREATMENT

Brief summary: This prospective, single-arm, multi-center, safety and feasibility first-in-human study will evaluate the safety and feasibility of the SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter to treat de-novo lesions between ≥2.0 and ≤4.0 mm in patients with symptomatic stable angina, unstable angina, and NSTEMI.

Detailed description: The SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter is an investigational medical device to be used to treat de-novo lesions in patients with symptomatic stable angina, unstable angina, and NSTEMI. In this study, SirPlux Duo™ will be used in subjects undergoing a planned percutaneous coronary intervention. The population to treat will include those with de-novo coronary lesions in vessels with a reference vessel diameter (RVD) of ≥2.0 and ≤4.0 mm and a total lesion length of \<36mm with documented symptomatic stable angina, unstable angina, or NSTEMI. The study is a prospective, single-arm, multi-center, safety and feasibility first-in-human study designed to generate descriptive data about the use of SirPlux Duo™.

Eligibility criteria: Inclusion Criteria:

1. The subject is ≥18 years and \<90 years old.
2. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed.
3. Subject has been diagnosed with a symptomatic stable angina, or acute coronary syndrome.
4. Life expectancy \> 1 year.
5. The subject is planned to undergo a percutaneous coronary intervention for a known lesion meeting the angiographic criteria set out below.
6. Women of child-bearing potential must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure. Men with a female partner of childbearing potential must agree to use condoms plus an additional reliable contraceptive method within 12 months after the index procedure.
7. The subject is able and willing to comply with all assessments in the study, including dual antiplatelet therapy (DAPT), ASA indefinitely, and P2Y12 inhibitor for a minimum of 6 months for stable angina subjects, and 12 months for unstable angina and NSTEMI subjects.
8. The subject shall be under optimal medical therapy for ASCVD, which includes at a minimum high-intensity statin therapy. If statin intolerant, the subject should be treated with a PCSK9 inhibitor, ezetimibe or bempedoic acid.

   Angiographic Inclusion Criteria:
9. Target lesion is located within a de-novo lesion located in a native coronary artery with a reference vessel diameter between and including 2.0 mm and 4.0mm by visual estimate, with an in-segment length \<=36mm. Target lesions must have a visually estimated stenosis of ≥50% and be \<100% in symptomatic subjects prior to lesion pre-dilation.
10. Subject has one or two lesions that meet inclusion and exclusion criteria individually that could be treated with a study device.

    If multiple lesions are treated, only two may be treated with the investigational device.

    If two lesions are treated with the investigational device, they must be in different vessels.

    Non-target lesions (lesion to be treated with something other than the investigational device) may be treated at either baseline or staged PCI but never in the same vessel as the target lesion.
11. Successful pre-dilation with semi and/or non-compliant balloon of the target lesion(s) (defined as no major flow-limiting dissections (Grade C or higher) and \<30% residual stenosis of the target lesion by a visual estimate on angiography). Adjunctive pre-dilation therapies such as scoring balloon, cutting balloon, and IVL are allowed. Rotablator or similar rotational atherectomy devices are restricted per protocol.

Exclusion Criteria:

General Exclusion Criteria:

1. Subject has current problems with substance abuse.
2. Subject has a planned procedure that may cause non-compliance with the protocol.
3. Subject participates in another investigational drug or device clinical study that has not reached its primary endpoint.
4. Subject intends to participate in another investigational drug or device clinical study within 12 months after the index procedure.
5. Chronic total occlusion (CTO) of the target lesion(s) or Thrombolysis In Myocardial Infarction (TIMI) flow \< 2.
6. Subject requires treatment of a coronary lesion(s) involving a bifurcation with significant ostial / proximal disease within 5mm of a side-branch greater than 2.0mm.
7. Target lesion(s) within native or synthetic vessel grafts.
8. Subject has had any major (e.g., cardiac, and non-cardiac) surgical procedure or intervention unrelated to this study within 30 days before the index procedure or has a planned major surgical procedure or intervention within 30 days of the index procedure. The exception will be made in case of planned staged PCI procedures for other coronary lesions (study or non-study lesion) lesions, whereby the timeframe between procedures shall be determined by the clinical stability of the subject as assessed by the treating investigator. The subject must re-meet the inclusion criteria and be free from any exclusion criteria before enrolment.
9. The subject has a known coagulopathy or has a bleeding diathesis, thrombocytopenia (with platelet counts less than 100,000/microliter) or platelets \> 450,000/microliter, or international normalized ratio \>1.5. Subjects on chronic oral anticoagulation medications will be excluded of the study.
10. Known renal insufficiency, estimated glomerular filtration rate (eGFR) ≤30 mL/min, by institutional calculation.
11. Subject on dialysis, or acute kidney failure (as per physician judgment).
12. Subject in whom antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated or hypersensitive.
13. Subject has a known allergy to contrast agents or medications used to perform a coronary intervention that cannot be adequately pre-treated, including, but not limited to, sirolimus, paclitaxel, aspirin, heparin, clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor.
14. Subject has a known allergy to urethane, nylon, or silicone.
15. Presentation and index admission with STEMI. An exception to this exclusion is the treatment of the non-culprit target lesion with study device during a staged PCI procedure which can be either during the index STEMI admission (but not at the time of primary PCI) or electively at another date.
16. Type 2 NSTEMI
17. Presentation with ACS and ongoing chest pain and/or hemodynamic instability despite treatment of the culprit lesion
18. History of stroke/TIA within 60 days before enrollment.
19. LVEF less than or equal to 35%.
20. Subject is confined to bed.
21. History of thrombolytic therapy within two weeks of enrollment.
22. Subject is a recipient of a heart transplant.
23. Subject is unwilling/not able to return for angiographic catheterization at 6-month follow-up.
24. Women who are pregnant, breast-feeding or intend to become pregnant.
25. Subject has other medical, social, or psychological problems and is unwilling or unable to comply with procedures specified in the protocol or may have difficulty returning for follow-up visits as specified by the protocol.
26. Cardiogenic shock (SBP \<80mmHg requiring inotropes, IABP, or fluid support).
27. Subject has symptomatic active COVID-19 or is asymptomatic within the past 2 weeks of a positive COVID test.

    Angiographic Exclusion Criteria:
28. Subject has a planned intervention in the left-main plus two separate major epicardial territories (left-main plus 2 vessel diseases).
29. Target vessel size \<2.00 mm or \>4.0 mm
30. Target lesion in the left main stem.
31. Target vessel with high thrombus burden.
32. Aorto-ostial target RCA lesion (within \< 10 mm of the aorta junction)
33. Moderate-severe tortuous, calcified, or angulated coronary anatomy of the target vessel that, in the opinion of the Investigator, would result in suboptimal imaging or excessive risk of complication from placement of an IVUS catheter following Clinical Decision.
34. The lesion is located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft.
35. Target lesion is located within a previous implanted stent.

Primary outcomes:
measure: Device Success
timeFrame: (Peri-procedural)
measure: Technical Success
timeFrame: (Peri-procedural)
measure: Procedural Success
timeFrame: (Peri-procedural)
measure: In-segment Late Lumen Loss (LLL) by QCA
timeFrame: 6 months post-procedure
Secondary outcomes:
measure: All-cause death
timeFrame: 24 hours post-discharge
measure: Target Vessel Myocardial Infarction (TVMI)
timeFrame: 30 days, 6 months, 12 months and 24 months post-procedure
measure: Major Adverse Cardiac Event (MACE)
timeFrame: 30 days, 6 months, 12 months and 24 months post-procedure
measure: Target Vessel Failure (TVF)
timeFrame: 30 days, 6 months, 12 months and 24 months post-procedure
measure: Target Lesion Failure (TLF)
timeFrame: 30 days, 6 months, 12 months and 24 months post-procedure
measure: All revascularizations (TLR, TVR and non-TVR)
timeFrame: 30 days, 6 months, 12 months and 24 months post-procedure
measure: In-segment (in balloon) percent diameter stenosis (%DS) by QCA
timeFrame: 6 months post-procedure
measure: In-segment binary angiographic restenosis (BAR) rate by QCA
timeFrame: 6 months post-procedure
measure: In-segment Minimum Luminal/Lumen Diameter (MLD) by QCA
timeFrame: 6 months post-procedure
measure: In-segment Change in IVUS minimum lumen area (MLA, mm2) by IVUS
timeFrame: at 6 months post-procedure
measure: In-segment change in mean lumen area (mm2) by IVUS
timeFrame: 6 months post-procedure
measure: In-segment change in percentage atheroma volume by IVUS
timeFrame: 6 months post-procedure
measure: In-segment serial IVUS remodeling
timeFrame: 6 months post-procedure
Other outcomes:
Locations:
city: Chermside
country: Australia
facility: The Prince Charles Hospital
state: Queensland
city: Adelaide
country: Australia
facility: Royal Adelaide Hospital
state: South Australia
city: Clayton
country: Australia
facility: Victorian Heart Institute - Monash University
state: Victoria
city: Santo Domingo
country: Dominican Republic
facility: Cecanot Hospital
city: Auckland
country: New Zealand
facility: Te Toka Tumai Auckland, Auckland City Hospital
Study officials:
affiliation: Monash Heart
name: Stephen Nicholls
role: STUDY_DIRECTOR
References: